Literature DB >> 23394354

Onyx embolization of intracranial arteriovenous malformations in pediatric patients.

Maryam Soltanolkotabi1, Samantha E Schoeneman, Tord D Alden, Michael C Hurley, Sameer A Ansari, Arthur J DiPatri, Tadanori Tomita, Ali Shaibani.   

Abstract

OBJECT: The authors undertook this study to assess the safety and efficacy of Onyx embolization in the treatment of intracranial arteriovenous malformations (AVMs) in pediatric patients.
METHODS: All pediatric Onyx embolization of intracranial AVM cases performed consecutively at a single children's hospital over a 5-year period were collected and evaluated.
RESULTS: Twenty-five patients (mean age 10.5 years) underwent a total of 38 procedures. An aggregate of 56 pedicles were embolized (mean 1.47 per session). The Spetzler-Martin grade was determined in all cases. Onyx embolization resulted in complete obliteration of the AVM in 3 cases (12%) and partial obliteration in 22 cases (88%). A total of 23 patients underwent surgical treatment. The mean preoperative AVM devascularization in these cases was 72%. One patient was treated with radiosurgery following Onyx embolization. Overall, 10 complications occurred in a total of 38 procedures (26.3%). None of the complications resulted in permanent neurological morbidity. The rate of transient neurological complications was 10.5% (4 of 38 procedures) and the rate of transient nonneurological complications was 5.3% (2 of 38 procedures). The remaining 4 complications were clinically silent (rate of 10.5%). There were no procedure-related deaths in this study population. There was no significant difference in patients with and without complications in terms of demographic characteristics, AVM grade, or embolization features (p ≥ 0.2). Deep venous drainage was associated with higher complication rates (p = 0.03).
CONCLUSIONS: Onyx utilization is feasible for preoperative or primary embolization in the treatment of pediatric intracranial AVMs; however, the spectrum of complications encountered is broad, and attention must be paid to the technical nuances of and indications for its use to avoid many potential dangerous effects. Although the overall complication rates were higher than expected, all were either clinically silent or had only transient clinical effects. Thus, this experience suggests that Onyx embolization can be performed safely with a low rate of permanent morbidity in pediatric patients harboring these difficult lesions.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23394354     DOI: 10.3171/2013.1.PEDS12286

Source DB:  PubMed          Journal:  J Neurosurg Pediatr        ISSN: 1933-0707            Impact factor:   2.375


  5 in total

1.  Curative embolization of pediatric intracranial arteriovenous malformations using Onyx: the role of new embolization techniques on patient outcomes.

Authors:  L H de Castro-Afonso; G S Nakiri; R S Oliveira; M V Santos; A C Dos Santos; H R Machado; D G Abud
Journal:  Neuroradiology       Date:  2016-02-24       Impact factor: 2.804

Review 2.  Arteriovenous Malformations in the Pediatric Population: Review of the Existing Literature.

Authors:  Mohammad El-Ghanem; Tareq Kass-Hout; Omar Kass-Hout; Yazan J Alderazi; Krishna Amuluru; Fawaz Al-Mufti; Charles J Prestigiacomo; Chirag D Gandhi
Journal:  Interv Neurol       Date:  2016-09-01

3.  The role of spinal angiography in the evaluation and treatment of pediatric spinal vascular pathology: a case series and systematic review.

Authors:  Eric Goethe; Melissa A LoPresti; Peter Kan; Sandi K Lam
Journal:  Childs Nerv Syst       Date:  2019-08-14       Impact factor: 1.475

Review 4.  Multimodality Neuromonitoring in Pediatric Neurocritical Care: Review of the Current Resources.

Authors:  Michael A Galgano; Zulma Tovar-Spinoza
Journal:  Cureus       Date:  2015-11-20

5.  Chemotherapy and surgical approach with repeated endovascular embolizations: safe interdisciplinary treatment for kasabach-merritt syndrome in a small baby.

Authors:  Ghassan Nakib; Valeria Calcaterra; Pietro Quaretti; Lorenzo Paolo Moramarco; Giovanni Bonalumi; Marco Brunero; Gloria Pelizzo
Journal:  Case Rep Oncol       Date:  2014-01-10
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.